Search the Newsreel

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Therapeutics Inc. announced its Q2 2026 financial results, with total revenue of $33.4 million and U.S. XPOVIO net product revenue of $30.8 million, reaffirming its full-year 2026 revenue guidance. The company remains on track to submit its supplemental New Drug Application (sNDA) in …

Argent Biopharma Limited (ASX:RGT) Share Price Falls 5.00% as Stock Trades Within Daily Range

Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary

Zenas BioPharma, Inc. (ZBIO) reported its financial results for the quarter ended 2026, showing revenue of $1M and a net loss of ($111.46M), with a diluted loss per share of ($1.77). These figures represent a significant decrease in revenue and an increase in net …

Form 8K Zenas Biopharma Inc For: 13 August By Investing.com

This article is a brief financial announcement from Investing.com, stating that Zenas Biopharma Inc. filed a Form 8K on August 13th. The filing is related to the company's financial activities and includes the stock symbol ZBIO, which showed a -6.68% change. The content primarily …

Analysts Offer Insights on Energy Companies: Conocophillips (COP), Excelerate Energy, Inc. Class A (EE) and Amplify Energy (AMPY)

Three analysts have issued bullish sentiments on energy companies: Conocophillips (COP), Excelerate Energy, Inc. Class A (EE), and Amplify Energy (AMPY). Josh Silverstein from UBS reiterated a Buy rating on Conocophillips with a $153.00 price target. Bobby Brooks from Northland Securities maintained a Buy …

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss

Zenas BioPharma (ZBIO) announced a Q2 loss of $1.77 per share, which is significantly wider than FactSet's estimated loss of $1.12 per share. The company reported Q2 revenue of $1.0 million. Zenas BioPharma is a clinical-stage biopharmaceutical company focused on autoimmune diseases with lead …

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma announced its second quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of the obexelimab BLA for IgG4-RD with a PDUFA date of May 27, 2027. The company also reported positive Phase 3 INDIGO trial results for obexelimab, …

Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M

Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss

Zenas BioPharma (ZBIO) reported a second-quarter 2026 net loss of $111.5 million on $1.0 million in revenue, an increase from a $52.2 million net loss in the prior-year quarter. The company ended the quarter with $673.9 million in cash and investments, and its biologics …

Radiopharm Theranostics Calls Virtual Extraordinary General Meeting for September 2026

Citizens cuts Sutro Biopharma stock price target on revenue miss

Clover Biopharmaceuticals Sets Board Meeting to Approve Interim Results and Consider Dividend

Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP

Tema ETFs LLC has acquired a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP), purchasing 57,034 shares valued at approximately $1.98 million, representing a 0.12% stake. This investment is part of broader institutional interest, with other major firms also adjusting their holdings in the company. …

ConocoPhillips starts production at Coyote 3SX on Alaska’s North Slope

ConocoPhillips Alaska, a subsidiary of ConocoPhillips, has commenced oil production at its Coyote 3SX development in the Kuparuk River Unit on State of Alaska land on the North Slope. The milestone was achieved ahead of schedule and under budget, said ConocoPhillips. The company approved …

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

Aspire Biopharma Holdings, Inc. announced its participation in Sidoti & Company's Micro-Cap Virtual Investor Conference on August 19-20, 2026. Management will host one-on-one meetings and discuss its clinical pipeline and recent acquisition of Dura Driver Control Systems. The presentation is scheduled for August 19, …

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages

Lyell Immunopharma (NASDAQ:LYEL) has received an average recommendation of "Moderate Buy" from nine brokerages, with an average 12-month price target of $42, significantly higher than its current trading price. Despite the positive analyst sentiment, the company remains unprofitable, reporting a quarterly loss of $1.92 …

XTLB Stock Surges 90%, Breaches 200-DMA For First Time In Over 3 Months – Here’s What The Acquisition Of Psyga Bio Brings To The Table

Vor Biopharma (VOR) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks

Argent BioPharma (ASX:RGT) Expands CannEpil Global Deal Into Animal Health With Second Royalty Opportunity

Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com

This article reports on an 8K filing by Arbutus Biopharma Corp (ABUS) for August 12. The brief announcement from Investing.com indicates this is a financial market update. No specific details about the content of the 8K filing are provided within the article.

Connect Biopharma Holdings earnings beat by ¥0.34, revenue topped estimates

Connect Biopharma Holdings (NASDAQ: CNTB) reported stronger-than-expected Q2 earnings, with an EPS of ¥-1.820, beating analyst estimates by ¥0.34. The company's revenue reached ¥18.67M, significantly surpassing the consensus estimate of ¥226.48K. Despite this, the stock has seen a 2.100% decline in the last three …

Connect Biopharma Holdings earnings beat by ¥0.33, revenue topped estimates

Connect Biopharma Holdings (NASDAQ: CNTB) reported stronger-than-expected Q2 earnings, with an EPS of ¥-1.820, beating analyst estimates by ¥0.34. The company's revenue reached ¥18.67M, significantly surpassing the consensus estimate of ¥226.48K. Despite this, the stock has seen a 2.100% decline in the last three …

Is Sutro Biopharma Inc (STRO) Facing Pressures After Q2 Earnings

Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million

Connect Biopharma reported a Q2 2026 net loss of $17.3 million, an increase from $12.9 million in Q2 2025, primarily due to a doubling of R&D expenses to $16.3 million for Phase 2 clinical trials. Despite the widening loss, license revenue surged to $2.8 …

SUTRO BIOPHARMA, INC. 2Q 2026: Revenue $9.84M, EPS ($2.33) — 10-Q Summary

Sutro Biopharma (STRO) reported second-quarter 2026 results with a significant revenue decline to $9.84M and a widened GAAP net loss of $38.53M, or $2.33 diluted EPS, primarily due to the derecognition of revenue from Ipsen. Despite the financial downturn, the company made clinical progress …

Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open

Arbutus Biopharma (ABUS) recently became profitable, with a significant surge in revenue and net income in Q2 2026, leading to a low trailing P/E of 5.6x. Despite this financial improvement, the stock has seen a muted market reaction and recent declines, suggesting investors are …

ConocoPhillips’ $800 million Coyote project delivers first North Slope oil ahead of schedule

ConocoPhillips Alaska has successfully brought its $800 million Coyote 3SX development on the North Slope online, achieving first oil ahead of schedule and under budget. This project is expected to reach a peak production of 12,000 barrels per day, contributing to Alaska's royalties and …

Radiopharm Theranostics Calls Extraordinary General Meeting to Ratify Placement Shares and Approve Capital Raising

Radiopharm Theranostics Limited (ASX:RAD) has announced an Extraordinary General Meeting (EGM) for September 11, 2026, to seek shareholder approval for various share issuances and capital raising activities. Shareholders will vote on ratifying previously issued placement shares and ADS shares, and approving the issuance of …

Radiopharm Theranostics Announces Virtual EGM on September 11, 2026 to Approve Share Issuances and Capital Raise

Radiopharm Theranostics Limited (ASX:RAD) has scheduled a virtual Extraordinary General Meeting (EGM) for September 11, 2026, to seek shareholder approval for various share issuances and capital raising initiatives. Shareholders will vote on ratifying previously issued shares, approving new placements to sophisticated investors, and endorsing …

Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Connect Biopharma (NASDAQ:CNTB) reported quarterly earnings results, with a loss of $0.27 per share, outperforming the consensus estimate of $0.32 by $0.05. Shares rose to $2.33 in midday trading, and the company maintains a "Moderate Buy" consensus rating from analysts with an average price …

ABVC BioPharma (ABVC) plans new equity plan and up to 6.6M-share land deal

ABVC BioPharma is seeking shareholder approval for a new 2026 Equity Incentive Plan, the ratification of 600,000 shares previously granted to advisors, and authorization to issue up to 6,638,591 shares for land acquisitions in Taiwan. The land deal is a related-party transaction with director …

ConocoPhillips Welcomes First Oil from Coyote Project in Kuparuk Unit

ConocoPhillips Alaska has announced that its Coyote project in the Kuparuk River Unit has achieved first oil ahead of schedule, delivering crude on August 7. The $800 million project, the fiftieth drill site in the Greater Kuparuk Area, is expected to reach a peak …

AVBP: Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026

ArriVent BioPharma (AVBP) is making strong clinical progress with its late-stage oncology pipeline, particularly with firmonertinib for EGFR-mutant NSCLC. The company also has next-generation ADCs targeting GI and solid tumors advancing. Significant clinical and financial milestones are anticipated in the second half of 2026.

ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS

ArriVent BioPharma (NASDAQ:AVBP) reported a quarterly loss of $1.05 per share, missing analysts' consensus estimates by $0.07. Despite the earnings miss, the company's shares rose by 0.2% to $31.46, and institutional investors own 9.48% of the stock. Analyst sentiment remains "Moderate Buy" with an …

Cue Biopharma (CUE) registers 1.51M shares for stockholder resale after $50M raise

Cue Biopharma (CUE) has filed a shelf registration to allow existing investors to resell up to 1.51 million shares of common stock, stemming from a $50 million private placement in July 2026. The company will not receive proceeds from these resales, except for nominal …

ArriVent BioPharma (NASDAQ: AVBP) details $93M loss and $373M cash buffer